Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2

Model NO.
184475-35-2
Storage Condition
Store at Rt
Transport Package
Aluminium Foil Bag
Specification
kg
Trademark
FOUSI
Origin
China
HS Code
2934999090
Production Capacity
100000kg/Month
Reference Price
$ 9.00 - 108.00
Contact Us

Product Description

 

Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2


Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2
 
Product Description
 
 
Product Name:Gefitinib
Synonyms:N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Gefitinib;Gefitinib, >=99%;N-(3-Chlor-4-fluorophenyl)-7-[methoxy-6-[(3-morpholin-4-yl)propoxyl]-quinazolin-4-yl]amine;GEFITINIB RELATED COMPOUND;Gefitinib N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;IRESSA;GEFITINIB;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
CAS:184475-35-2
MF:C22H24ClFN4O3
MW:446.9
EINECS:643-034-7
Product Categories:API;IRESSA;Active Pharmaceutical Ingredients;Gefitinib;Molecular Targeted Antineoplastic;Anti-cancer&immunity;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;APIs;Inhibitors;Anticancer
 
Product picture

 

Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2

Product Parameters
Melting point 119-1200C
Boiling point 586.8±50.0 °C(Predicted)
density 1.322±0.06 g/cm3(Predicted)
storage temp. room temp
pka7.00±0.10(Predicted)
form powder
color white to beige
  
Gefitinib is an antineoplastic target therapy drug with relatively high specificity that was developed by the British pharmaceutical company AstraZeneca; it is the first molecular targeted drug to be used in non-small cell lung cancer treatment. Epidermal growth factors (EGF) are a kind of polypeptide with a relative molecular mass of 6.45x103, and they can bind with epidermal growth factor receptors (EGFR) on target cell membrane surfaces to trigger biological effects. EGFR is a type of tyrosine kinase (TK) type receptor, so when bound with EGF, it will promote TK activation in the receptor. This will cause tyrosine residue in the receptor to autophosphorylate and send continuous dividing signals into the cell, causing cell proliferation and differentiation. EGFR is abundant in human tissue, and it is highly expressed in malign tumors. Gefitinib blocks the signal transduction pathway of cell surface EGFR to prevent tumor growth, metastasis, and growth in blood vessels, and it can induce tumor cell apoptosis. Gefitinib is mainly used to treat non-stem cell lung cancer.
Packaging & Shipping

 

Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2

Company Profile

 

Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2
 
FAQ

 

Factory Supply Pharmaceutical Gefitinib CAS 184475-35-2

 

Pharmaceutical Intermediate

PNEUTEC.IT, 2023